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Studies on the mechanism of trimethoprim-induced hyperkalemia. We
examined the effects of trimethoprim (TMP) on metabolic parameters and
renal ATPases in rats after a 90 minute infusion (9.6 mg/hr/kg body wt,
i.v.) and after 14 days (20 mg/kg body wt/day, i.p.). After one dose of TMP,
plasma electrolytes, arterial pH and aldosterone levels were normal, but a
natriuresis, bicarbonaturia, and decreased urinary potassium excretion
occurred. Na-K-ATPase activity in microdissected segments from these
animals was decreased by 36 0.9% in proximal convoluted tubule (PCT)
(P < 0.005); decreases of 50 2.1% and 40 1.1% were seen in cortical
and medullary collecting tubules (CCT and MCT), respectively (P <
0.005). Na-K-ATPase activity was unaffected in medullary thick ascending
limb (MTAL). H-ATPase (in PCT and collecting duct) and H-K-ATPase
(in CCT and MCT) activities were not changed. Following chronic TMP
administration, plasma potassium increased as compared to control (5.16
0.05 mEq/liter vs. 3.97 0.05 mEq/liter, P < 0.05), however, acid-base
status and plasma aldosterone levels were normal. Na-K-ATPase activity
was decreased by 45 2.6% in PCT (P < 0.005), 73 2.0% in CCT (P
< 0.001), and 53 2.5% in MCT (P < 0.005). Na-K-ATPase activity in
MTAL and H-K-ATPase activity in CCT and MCT were unchanged.
H-ATPase activity in PCT and MTAL was normal, but in the collecting
tubule (CCT and MCT) it was decreased by approximately 25% (P <
0.05). TMP inhibited Na-K-ATPase activity in a dose-dependent fashion
in PCT, CCT, and MCT when tubules from normal animals were
incubated in vitro with the drug; TMP in vitro did not affect H-ATPase or
H-K-ATPase activity. These results suggest that TMP-induced hyperkale-
mia may result from decreased urinary potassium excretion caused by
inhibition of distal Na-K-ATPase in the face of intact H-K-ATPase
activity.
The drug trimethoprim-sulfamethoxazole (Bactrim®) is widely
used as an antimicrobial agent, being effective against both
gram-positive and gram-negative organisms [1]. Renal disorders
associated with its use include decreased creatinine secretion,
interstitial nephritis, and hyponatremia [2, 3]. Recently, the drug
has been advocated both for therapy and prophylaxis of Pneumo-
cystis carinii pneumonia in patients with the acquired immunode-
ficiency syndrome [4, 5], Clinical studies show that over 20% of
the patients develop hyperkalemia when a regimen of 20 mg/kg!
day is given for more than one week [6—8]. The renin-angiotensin-
aldosterone axis appears to be "intact" in those few patients
studied, and the hyperkalemia disappears when the drug is
discontinued [6—9].
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Trimethoprim (TMP), one of the two active components of
Bactrim®, is a pyrimidine derivative (pKa 7.3) [10] which, when
infused into rats, causes a natriuresis and a fall in urinary
potassium excretion [11], In perfused rat-distal tubule, Velázquez
et al [11] showed TMP decreased net potassium secretion and
transepithelial voltage. In the frog skin, a model of the mamma-
lian collecting duct, TMP decreases short circuit current and Na22
flux. Amiloride was found to competitively displace TMP with a
Kd of 46 X io M (Kd of TMP is 53 X iO M) [12]. Recent
studies show that TMP also blocks an amiloride-sensitive sodium
channel in A6 cell monolayers, a model of mammalian cortical
collecting tubule principal cells [13].
The collecting tubule is the final site for regulation of urinary
potassium excretion and urinary acidification [14, 15]. Potassium
secretion at this site is modulated by Na-K-ATPase activity and
reabsorption is mediated by H-K-ATPase activity [15, 16]. Inhi-
bition of the former results in hyperkalemia and inhibition of the
latter would result in kaliuresis. Proton transport in the collecting
tubule is controlled by both the H-ATPase and the H-K-ATPase,
enzymes found in the a-intercalated cells [15, 16]. As the effect of
TMP on these renal transport enzymes is unknown, we examined
acute and chronic administration of the drug to rats in microdis-
sected permeabilized nephron fragments. We also studied the
direct effect of the drug in vitro.
Methods
Male Sprague-Dawley rats weighing 100 to 200 g were used in
this study. All animals had free access to the usual laboratory diet
and were given tap water to drink ad libitum, unless otherwise
noted.
In vivo studies
A. Acute study (single dose intravenous infusion). Animal prepa-
ration. Animals were first anesthetized with sodium pentobarbital
and ketamine. The femoral vein was then catheterized with PE-50
tubing for continuous infusion; the femoral artery was cannulated
for blood samples [17]. A solution containing NaCl (140 mEq/
liter) and KC1 (4 mEq/liter) (pH 7.4) was infused at 15 ml!hr/kg
body wt and was the vehicle for TMP. The bladder was cannulated
for urine collection to determine glomerular filtration rate (as
measured using creatinine clearance) and electrolyte excretion
[18]. A blood sample (0.5 ml) was obtained at the midpoint of
each urine collection. One hour was allowed for equilibration
before the beginning of the clearance collections. Three urine
collections (30 mm) were made as baseline data and three
collections (30 mm) were obtained during the experimental
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period. All blood and urinary losses were replaced with the
solution described above. The animals were divided into the
following groups (N = 6 in each group):
Group 1: Control (cj). The animals received the salt solution
intravenously during the baseline and experimental periods.
Group 2: Trimethoprim (TMP). After the baseline period,
animals received 0.64 g/liter TMP at a rate of 9.6 mg/hr/kg body wt
throughout the experimental period. Previous work has shown
that this dose results in a natriuresis and decreased urinary
potassium excretion [11].
B. Chronic study (14 days intraperitoneal administration). Animal
preparation. A twenty-four hour urine collection was performed
on each animal as baseline after three days on a diet of standard
composition (ICN Pharmaceuticals Inc., Costa Mesa, CA, USA)
and 0.3% NaCI p.o. ad libitum to prevent volume contraction as
we have described [18]. The animals were then divided into the
following groups (N = 6 in each group):
Group 1: Control (. The animals were treated daily (x 14
days) with the vehicle described below (0.75 ml, i.p.).
Group 2: Trimethoprim (TMP). The animals were treated daily
with TMP (20 mg/kg/day, i.p.) for 14 days. TMP (16 mg/mI) was
dissolved in 40% propylene glycol, and at the time of injection was
diluted to 0.75 ml (total volume) with distilled H20 for i.p.
administration [101.
On the morning of the thirteenth day, the animals were again
placed in metabolic cages for a 24-hour urine collection. On the
day of the experiment, after receiving the final TMP dose, the
animals were anesthetized and blood samples were obtained from
the aorta for measurement of pH, pCO2, creatinine, electrolytes,
and aldosterone,
Arterial blood gas, urine and plasma electrolytes and creatinine
were measured as we have published in the past [17, 18].
Potassium concentration in muscle, renal cortex, and renal me-
dulla was measured by atomic absorption spectrophotometty;
plasma aldosterone concentration was determined by radioimmu-
noassay (COAT-A-COUNT® DPC, Los Angeles, CA, USA) [18].
Tubules microdissection and enzymatic measurements
Tubules were microdisseeted as we have previously described in
detail [18, 19]. In brief, the left renal artery was cannulated and
the kidney was perfused for 15 minutes in situ at a rate of 0.7
mI/mm with a balanced salt solution containing 400 U/ml colla-
genase; 4°C, pH 7.4. The kidney was then cut into 5 X 5x10 mm
pyramids along the cortico-papillary axis and incubated in 3 ml of
collagenase-albumin containing Hank's solution at 35°C for 12
minutes, pH 7.4. The tissues were continuously bubbled with
compressed air (3 psi). After incubation, the pyramids were rinsed
and immediately microdissected. Tubule segments were identified
as proximal convoluted tubule (PCT), medullary thick ascending
limb of Henle's loop (MTAL), cortical collecting tubule (CCT),
and medullary collecting tubule (MCT) [18, 19].
To remove most of the extracellular potassium, nephron seg-
ments were incubated for 15 minutes at 37°C (pH 7.4) in
potassium-free buffer. The nephron segments were then subjected
to a two-step hypotonic-hypothermic shock and ATPase activities
were determined after incubation of the segments with y32P-
labeled ATP (37°C, 15 mm, pH 7.4). H-ATPase (N-ethylmaleim-
ide-inhibitable), H-K-ATPase (K-stimulated), and Na-K-ATPase
(ouabain-inhibitable) were measured by the radiochemical
method of Doucet and Marsy [20] as subsequently described by us
[21]. All assays were performed at V,1, conditions (12 mM ATP,
pH 7.4 and 37°C) [21].
in vitro study
To further examine the direct effect of TMP on the three renal
ATPases, additional in vitro studies were performed in a manner
we have described for amiloride [19, 22]. Segments of PCT, CCT,
and MCT were first microdissected from acclimated normal
Sprague-Dawley rats. After the hypotonic-hypothermie shock,
tubule segments were pre-incubated for 90 minutes in vitro in 1.2
d of buffer with varying concentrations of TMP (0.01 to 10 mM).
After the preincubation period, the solution was then replaced
with one appropriate for the enzyme analysis to be performed
(that is, H-ATPase, H-K-ATPase and Na-K-ATPase). ATP (12
mM) plus y32P-ATP was added and the reaction was allowed to
proceed for 15 minutes at 37°C, pH 7.4.
Enzyme activity is expressed as pmol/mm tubule length/hour of
ATP hydrolyzed. All samples were run in triplicate or quadrupli-
cate and appropriate corrections were made for the blank and for
the spontaneous hydrolysis of ATP [21].
Materials
All chemicals and reagents were obtained from the Sigma
Chemical Co. (St. Louis, MO, USA) and were of highest purity.
Radiolaheled ATP (high specific activity) was obtained from New
England Nuclear (Boston, MA, USA). Trimethoprim was gra-
ciously provided by the Roche Laboratories (Nutley, NJ, USA).
Statistics
Statistical significance was assessed using the Student's t-test
(paired or unpaired) or analysis of eovariance, where appropriate,
with P values of 0.05 or less being significant.
Results
Effects of trimethoprim infusion on metabolic parameters and
renal function
Acute infusion. There was no significant difference in any of the
blood values or in ereatinine clearance after a single TMP infusion
was given to rats (Table 1, upper panel). Acid-base status, plasma
potassium (and other electrolytes) and aldosterone levels were
similar to control. The slight, but significant, increase in urine
sodium excretion seen in the experimental period of control
animals was due to the volume expansion caused by the infusion
of the salt solution use as the vehicle (Table 1, lower panel).
Following the same protocol, however, TMP-treated rats had a
greater and significant natriuresis (P < 0.01) and bicarbonaturia
(P < 0.01), as well as a decrease in urinary potassium excretion (P
< 0.05). While TMP infusion did not change urine flow rate or
chloride excretion, urine pH increased (P < 0.05).
Chronic administration. There was no significant difference in
body wt between the two groups of animals after 14 days,
indicating normal growth throughout the study. In control ani-
mals, mean body wt was 104 2 g on Day 0 and after 14 days,
body wt was 177 4 g; in the TMP-treated animals, body wt was
103 2 g and 173 3 g, respectively (NS). As shown in Table 2
(upper panel), TMP-treated animals had normal acid-base status,
normal plasma sodium and chloride concentrations, but plasma
potassium was significantly higher than control (5.16 0.05
mEq/liter vs. 3.97 0.05 mEq/liter, respectively, P < 0.05).
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Table 1. Effect of a single infusion (9.6 mg/kg/hr for 90 mm) of trimethoprim on metabolic parameters and renal function in rats
Body wt Aldosterone pCO2
g ng/dl pH mm Hg
HCO3 'Na
mI/mint] 00 gmEq/liter
Control 170 3 27 2 7.39 0.01 40 1 23.3 0.1 140 1 3.98 0.05 98 1 0.81 0.01
TMP 172 4 25 2 7.38 0.01 40 0.6 23.0 0.6 138 1 4.28 0.05 99 1 0.71 0.02
Abbreviation is: Ce,, creatinine clearance, N = 6 in each group; NS.
Group U.s, UH U03V UNaV UKV U1V
Control Baseline 11.2 0.31 6.60 0.06 179 8 1361 39 589 22 1804 36
Exptl 13.3 0.34 6.58 0.05 188 6 1627 69 629 17 1992 41
TMP Baseline 11.0 0.39 6.55 0.05 183 7 1379 49 595 19 1857 52
Exptl 13.8 0.34 7.02 0.04a 387 20b 2114 48b 306 15 2007 42
Abbreviations are: U.,,,, Urine flow rate (JAJ/min); UHcoV, urine bicarbonate excretion (nmol/min); UNaV, urine sodium excretion (nmol/min); UKV,
urine potassium excretion (nmol/min); UV, urine chloride excretion (nmol/min), Exptl, experimental period; N = 6 in each group.
a P < 0.05, b p < 0.01 vs. baseline of the same group and experimental of the control group
Table 2. Effect of chronic trimethoprim administration (20 mg/kg for 14 days) on metabolic parameters and renal function in rats
Aldosterone
ng/dl pH
pCO2 HCO3 Na
mm Hg mEqiliter
c1 Cr
ml/min/100 g
Control 28 2 7.40 0.01 41 1 23.3 0.04 141 1 3.97 0.05 98 1 0.76 0.02
TMP 30 2 7.39 0.01 42 2 22.6 0.05 139 1 5.16 0.05a 99 2 0.66 0.02
Abbreviation is: Ce,, creatinine clearance. N = 6 in each group. a P < 0.05 vs. Control.
Group U UPH UHC03V UNaV UKV U1V
Control Pre 9.6 0.2 6.58 0.07 271 14 1633 61 2469 96 1678 65
Post 9.8 0.2 6.60 0.08 280 14 1749 62 2603 163 1683 63
TMP Pre 9.8 0.2 6.55 0.07 268 19 1647 58 2537 80 1728 113
Post 10.0 0.2 7.00 0.06a 656 74" 1839 54 1954 40 1705 56
Abbreviations are: U,,,, urine volume/24 hours (expressed/100 g body wt); U,03V, urine bicarbonate/24 hours; UNaV, urine sodium/24 hours; UKV,
urine potassium/24 hours; U,V, urine chloride/24 hours; Pre, pre-treatment; Post, post-treatment; urine electrolyte excretion is expressed as sEq/100
g body weight/24 hours. N = 6 in each group.
ap < 005 bp <0.01 Pre vs. Post TMP.
Despite the hyperkalemia, however, plasma aldosterone was not
different from the controls (30 2 ng/dl vs. 28 2 ng/dl,
respectively, NS). Chronic TMP therapy resulted in bicarbonatu-
na (P < 0.01) and a fall in urinary potassium excretion (P < 0.05)
(Table 2, lower panel). Urine flow and sodium chloride excretion
were unchanged presumably reflecting a new steady state of salt
balance after 14 days of TMP therapy.
Effect of trimethoprim on potassium stores
Analysis of muscle and renal tissue (cortex and medulla)
revealed that potassium concentration was unaffected after TMP,
either following a single infusion or after 14 days. Control values
in muscle, renal cortex and medulla were 0.38 0.01, 0.28 0.02
and 0.30 0.02 mEq/g dry wt, respectively; after 14 days of TMP
the values were 0.36 0.01, 0.26 0.01 and 0.38 0,02 mEq/g
dry wt, respectively (N = 8 to 12 samples per organ per group;
NS). (Statistically identical results were obtained for the acute
infusion study, data not shown.)
In vivo effects of trimethoprim on renal A TPases
Acute infusion. Na-K-ATPase activity in microdissected seg-
ments from TMP-treated rats was decreased by 36 0.9% in PCT
(P < 0.005), 50 2.1% in CCT (P < 0.005), and 40 1.1% in
Ti 1rr
MCT (P < 0.005) (Fig. 1). TMP infusion had no effect on
Na-K-ATPase activity in MTAL. Neither H-K-ATPase (Fig. 2)
nor H-ATPase (Fig. 3) activity was affected in TMP infusion-
treated animals (H-K-ATPase activity was examined only in
collecting tubule segments).
Chronic administration. The effect of chronic treatment with
TMP on Na-K-ATPase activity is shown in Figure 4. Enzyme
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Fig. 1. Effect of a single infusion of trimerhoprim (shaded bars) on Na-K-
A TPase activity in PCT, MTAL, CCT, MCT; N 6 in each group; *1) <
0.005 versus control animals.
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Fig. 4. Effect of chronic (14 days) trimethoprim administration (shaded
bars) on Na-K-A TPase activity in PCT, MTAL, CCT, MCT; N 6 in each
group; *]) < 0.005, tP < 0.001 versus control animals.
activity was decreased, as compared to control, by 45 2.6% in
PCT (P < 0.005), by 73 2.0% in CCT (P < 0.001), and by 53
2,5% in MCT (P < 0.005). Chronic drug treatment, again, did not
affect Na-K-ATPase in MTAL. H-K-ATPase activity in CCT or in
MCT was not different from their respective controls (Fig. 5). In
contrast to the lack of effect of a single dose of TMP to alter
H-ATPase activity in the collecting tubule (Fig. 5), chronic TMP
treatment decreased the enzyme significantly; in CCT, it was
decreased by 21 1,3% (P < 0.05), and in MCT it fell by 24
1.5% (P < 0.05) (Fig. 6). H-ATPase activity, however, did not
change in either PCT or MTAL.
POT MTAL CCT MCT
Fig. 6. Effrct of chronic (14 days) trimethoprim administration (shaded
bars) on H-ATPase activity in PC7 MTAL, CCT, MCT; N = 6 in each
group; *JJ < 0.05 versus control animals.
In vitro effects of trimethoprim on renal A TPase enzymes
To further examine the direct action of TMP on the three renal
transport enzymes, we incubated the drug in vitro (0.01 to 10 mM)
with tubule segments from normal animals (Table 3). Tn-
methoprim had a direct inhibitory effect on Na-K-ATPase in PCT,
CCT, and MCT; it was without effect in MTAL, At 0.1 mri TMP,
enzyme activity was decreased by 28 1.1% in PCT (P < 0.05),
30 1.1% in CCT (P < 0.05), and 27 1.3% in MCT (P < 0.05).
There was a further, and significant, decrease in Na-K-ATPase
activity in each of the three segments when the concentration of
TMP was increased to 1,0 m. The percentage decrease, as
compared to controls, was 53 4.2% in PCT (P < 0.01), 54
4,5% in CCT (P < 0.01), and 36 1.7% in MCT (P < 0.01). The
highest concentration (10 mM TMP) did not decrease Na-K-
ATPase activity further.
The highest concentration of tnimethoprim (10 mM) had no
significant effect on H-K-ATPase or H-ATPase activity in any of
the segments studied (Table 3). In additional studies (N = 4), the
effect of 0,1 mM (100 I.LM) amiloride was examined, This agent,
well known to inhibit apical Na channels directly, did not change
H-K-ATPase or 1-I-ATPase activity when it was incubated with
collecting tubules microdissceted from normal animals, confirm-
ing results reported previously [19, 22]. However, this concentra-
tion of amiloride (100 ILM) decreased Na-K-ATPase in CCT from
905 26 pmol/mm/hr to 463 52 pmol/mm/hr (P < 0.01, N = 4).
: 200
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Fig. 2. Effect of a single infusion of trimethoprim (shaded bars) on H-K-
A TPase activity in CCT and MCT; N = 6 in each group (Control vs. TMP,
NS).
CCT MCT
200
100
0
Fig. 5. Effect of chronic (14 days) trimethopnm administration (shaded
bars) on H-K-A TPase activity in CCT and MCT; N = 6 in each group
(Control vs. TMP, NS).
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Fig. 3. Effect of a single infusion of trimethoprim (shaded bars) on 11-
ATPase activity in PCT, MTAL, CCT, MCT; N = 6 in each group (Control
vs. TMP, NS).
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Table 3. In Vitro effect of trimethoprim (TMP) on renal ATPases in microdissected rat nephron segments
Enzyme Group PCT MTAL CCT MCT
Na-K-ATPase
H-K-ATPase
Control
TMP (0.01 mM)
TMP (0.1 mM)
TMP (1.0 mM)
TMP (10.0 mM)
Control
TMP(lOmM)
2276 134
2127 107
1637 67
1067 85b
923 54"
ND
ND
4075 160
3987 103
3968 79
3942 70
3936 64
ND
ND
903 22
903 22
639 24
418 35"
382 34"
184 8
178± 14
815 12
802 16
598 29
518 25"
510 16"79 7
75±5
H-ATPase Control
TMP(lOmM)
480 11
414±17
275 14
260±11
270 15
264±15
233 12
211±12
Values are means SE expressed as pmol/mm/hr; N = 6 in each group. ND is not done (see Methods for details, 90 mm pre-incubation with TMP).
aP < 0.05 vs. control "P < 0.01 vs. control and 0.1 mi TMP
Discussion
Trimethoprim is a widely used antimicrobial agent usually
administered to humans as trimethoprim-sulfamethoxazole
(Bactrim®). While the physico-chemistry and pharmacokinetics
in humans and other animals have been reviewed in detail in the
past [23—261, abnormalities in renal function and electrolyte
homeostasis seem to be occurring more frequently. Some of the
renal disorders associated with trimethoprim treatment include
decreased creatinine secretion, interstitial nephritis, and hypona-
tremia [2, 3] (Sulfamethoxazole appears to be without effect).
Recently, trimethoprim-induced hyperkalemia has been reported
in patients with the acquired immunodeficiency syndrome (AIDS)
who receive either high doses of the drug (20 mg/kg/day) or
prolonged therapy (7 days or more) for Pneumocystis carinii
pneumonia [4, 5]. The hyperkalemia appears to be reversible as it
ameliorates after withdrawal of the agent [6—8]. The mechanism
for the hyperkalemia is incompletely understood, but the renin-
aldosterone axis is reported to be intact in most, but not all, cases
[5, 9, 27]. Metabolic acidosis has also been seen in patients
without AIDS who received long-term high-dose trimethoprim,
although its incidence is far less than is the hyperkalemia.
The collecting tubule plays a major role in potassium secretion
and sodium reabsorption, processes which depend, in part, on the
basolateral Na-K-ATPase pump. Inhibition of the enzyme would
affect the transport of both actions. Sodium wasting would occur,
although its magnitude may not be substantial if the enzyme were
intact in other parts of the nephron. Net potassium balance in
collecting tubule results as a combination of secretion via K
channels and luminal reabsorption via activity in the H-K-ATPase
pump localized to a intercalated cells. Inhibition of Na-K ATPase
would result in hyperkalemia as the gradient across as the
basolateral membrane would be dissipated. If collecting duct H-K
ATP remained intact, K absorption would continue, making the
hyperkalemia more profound.
Velázquez et al [11] recently reported that an acute infusion of
trimethoprim inhibited potassium secretion and enhanced sodium
excretion in the in vivo perfused rat distal tubule. The decrease in
potassium excretion was 40% and the change in sodium transport
was twofold. The drug had no effect on urine flow rate or chloride
excretion, findings confirmed in the present study. Velázquez et al
[11] also showed a 50% decrease in transepithelial voltage when
0.1 mM trimethoprim was perfused. This dose is comparable to the
one which we showed to significantly inhibit collecting tubule
Na-K-ATPase activity in vitro.
Recent electrophysiologic measurements in the A6 cell line
demonstrate that 1 mtvi trimethoprim directly inhibits the amilo-
ride-sensitive Na channel [28]. Apical, but not basolateral,
administration affected the channels, suggesting that a direct
interaction of the drug with the outer channel pore is required.
Furthermore, the inhibitory effect of 1 mrvt trimethoprim on
short-circuit current was rapidly reversed by the subsequent
addition of amphotericin B (10—6 M) to the luminal bath [28]. The
authors postulated that trimethoprim did not alter Na-K-ATPase
or cellular metabolism since amphotericin B creates amiloride-
insensitive ion channels allowing sodium to enter cells freely. They
did not, however, measure Na-K-ATPase directly as we did in the
present study. After either a single dose or chronic administration,
trimethoprim was noted to inhibit Na-K-ATPase throughout the
nephron, with the singular exception being the thick ascending
limb. The pharmacologic agent also inhibited the enzyme when
incubated in vitro. The discrepancy between electrophysiologic
studies in an intact cell line in culture and our current biochemical
studies in permeabilized cells are unknown. It appears that the A6
cell line is more sensitive (that is, current inhibition) to tn-
methoprim. Our data, however, do support the notion that
trimethoprim's inhibition of short-circuit current is secondary to
its direct effect on Na-K-ATPase activity. We say this because in
vitro incubation of normal tubules with 0.1 mM TMP is associated
with a significant fall in enzyme activity; a greater decrease occurs
if the concentration is further increased (that is, to 1 mrvt TMP).
An additional explanation, however, is that trimethoprim may
affect both apical sodium channels (or potassium) and basolateral
Na-K-ATPase equally. Amiloride, a drug chemically similar to
trimethoprim, results in hyperkalemia when given chronically.
Amiloride also inhibits Na-K-ATPase when added to proximal
tubules on collecting duct segments in vitro [22, 29].
The present study also shows that chronic tnimethoprim admin-
istration causes hyperkalemia but acid-base status and plasma
aldosterone levels remain normal. Bicarbonaturia and a fall in
urinary potassium excretion were noted. Na-K-ATPase activity
decreased in a pattern similar to that observed in the short term
study, however, a more prominent fall was seen in the CCT.
Again, H-K-ATPase activity remained unchanged, but collecting
tubule H-ATPase activity was slightly decreased. Previous studies
by our laboratory [18], as well as by Garg and Narang [30], clearly
show that hyperkalemia inhibits H-K-ATPase activity. In the
present study, however, we found H-K-ATPase activity to be
normal in TMP-treated animals, despite the hyperkalemia. This
was an unexpected finding as the drug was not found to have a
direct effect on the enzyme when incubated in vitro (Table 3). To
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us, this suggests that there must be offsetting events when the drug
is administered ehronicalty, however, precisely what those events
are remain unknown at the present time.
Hyperkalemia is a well known potent stimulus for aldosterone
release [18]. In our studies, however, plasma aldosterone was
normal after chronic trimethoprim administration, despite a
plasma potassium of 5.6 mEq/litcr. Velázquez et al [11] reported
in 7 of 30 patients with normal renal function receiving high dose
trimethoprim (20 mg/kg/day) for a mean of five days, plasma
potassium was 5.9 0.9 mEq/liter. Plasma aldosterone levels in
these patients was slightly elevated with a mean of 19.3 9.5 ng/dl
(laboratory control values were 8.1 to 15.5 ng/dl). In the face of
hyperkalemia, we feel this is a suboptimal hormonal response, and
combined with the result of our study, suggests that trimethoprim
may indeed have a direct effect on the adrenal axis, possibly
inhibiting aldosterone synthesis or release.
The kidney is known to avidly concentrate the drug [25], but it
is not known whether the same occurs in the adrenal gland. If a
crucial step in aldosterone biosynthesis were inhibited, the hor-
monal response to hyperkalemia would be altered. If Na-K-
ATPase is required for aldosterone release, trimethoprim may
inhibit its activity in the zona glomerulosa in a manner similar to
that we observed in the kidney. These possibilities would explain
"normal" plasma aldosterone levels in the face of hyperkalemia.
Further studies are required to clarify this and to determine whether
it is of clinical relevance in either normal or "at risk" humans.
Our experiments show, as has been reported in humans, that
chronic trimethoprim results in bicarbonaturia, hut plasma bicar-
bonate and pH are normal. Such findings suggest that the drug
stimulates tissue buffer stores, While liver, bone or muscle are the
likely candidates for the enhanced extra-renal buffering, there are
no data in the literature examining this issue. Since trimethoprim
seems to be similar in many ways to amiloride, we searched the
literature for its effect on extra-renal buffering; we were unable to
find any data on amiloride, either.
Finally, our study shows that trim ethopim has no effect on Na-K
ATPase in thick ascending limb, either in vivo or in vitro. While we
have no ready explanation, it may be that there are different
isoforms of the enzyme in this segment of the nephron as
compared to other parts of the kidney. Further studies are
required to verify whether this speculation is true.
In conclusion, acute trimethoprim infusion causes a decrease in
urinary potassium excretion without hyperkalemia. This occurs in
association with a fall in Na-K-ATPase activity in the proximal
tubule and collecting duct. H-K-ATPase is normal. Long-term
trimethoprim administration results in hyperkalemia as well as
decreased potassium excretion. Na-K-ATPase activity was re-
duced in the proximal tubule, but a more prominent fall in the
enzyme was seen in the cortical collecting tubule. After chronic
administration there was a slight decrease in collecting tubule
H-ATPase activity, possibly explaining the biearbonaturia. In vitro,
trimethoprim causes a direct inhibition of Na-K-ATPase activity
in a dose-dependent fashion; the drug does not alter the H-
ATPase or H-K-ATPase activity in vitro. Trimethoprim must also
exert a direct effect on the adrenal axis as plasma aldosterone was
within the normal range despite the rather marked hyperkalemia.
Taken together, these data suggest that, from a functional stand-
point, trimethoprim "is" amiloride, and should be used judiciously
not only in the immunocompromised patient, but also in patients
with renal insufficiency.
Acknowledgments
This work was supported in part by grants from the National Institutes
of Health (No. R01-DK-36199) and the American Heart Association,
Texas Affiliate, Inc., (No. 92G-316). Somchai Eiam-ong, M.D. was the
recipient of the National Kidney Foundation Fellowship Award (USA).
The authors thank Mr. Lee Harwell for graphic assistance and Ms. Christy
Struud for typographical assistance.
Reprint requests to Sandra Sabatini, Ph.D., M.D., Department of Physiol-
ogy, Texas Tech University Health Sciences Center, 3601 4th Street, Lubboc!ç
Texas 79430, USA.
References
1. SALTER AJ: Trimethoprim-sulfamethoxazole: An assessment of more
than 12 years of use. Rev Infect Dis 4:196—236, 1982
2. KAUFMAN AM, HELLMAN 0, ABRAM50N RG: Renal salt wasting and
metabolic acidosis with trimethoprim-sulfamethoxazole therapy. Mt
Sinai J Med 50:238—239, 1983
3. LAWSON DH, PAICE BJ: Adverse reactions to trimethoprim-sulfame-
thoxazole. Rev Infect Dis 4:429—433, 1982
4. MaNNA I, MILLS J, LEOUNG 0, HOPEwELL PC, PHARM BL, MootN 0,
BEN0wITz N, Wovsv CB: Oral therapy for pneumocystis carinii
pneumonia in the acquired immunodeficieney syndrome. N Engi J
Med 323:776—782, 1990
5. LEE BL, MEOINA I, BENowtTz NL, JACOB P, W0F5Y CB, Miu.s J:
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during
treatment of pneumocystis pneumonia in patients with the acquired
immunodeficieney syndrome (AIDS). Ann mt Med 110:606—611, 1989
6. BNRNS iS, COHaN RM, STUMACHER RJ, RUDNICK MR: Renal aspects
of therapy for human immunodeficiency virus and associated oppor-
tunistic infections. JAm Soc Nephrol 1:1061—1080, 1991
7. GREENBERG 5, REI5ER 1W, CH0U S-Y, PORUSH JO: Trimethoprim-
sulfarnethoxazole induces reversible hyperkalemia. Ann Intern Med
119:291—295, 1993
8. GREENBERG 5, REI5ER 1W, CII0U SY: Hyperkalemia with high-dose
trimethoprim-sulfamethoxazole. Am J Kid Dis 22:603—606, 1993
9. Gitossvoot SK, BII.EzIKIAN JP: HIV disease and the endocrine
system. N EnglJ Med 327:1360—1365, 1992
10. The Merck Index (10th ed). Edited by WIN000I.z M, Rahway, Merck
& Co., Inc., 1983 (# 9516), p 1387
11. VELAZOUEZ H, PERAZEI.LA MA, WRIGHT FS, ELLI50N DH: Renal
mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med
119:296—301, 1993
12. FON5ECA PD, MOURA TF, FERREIRA KTG: The effect of trimethoprim
on sodium transport across the frog skin epithelium. Eur J Pharm
207:337—343, 1991
13. SCHLANGER I.E, KLEYMAN TR, LING BN: Ktsparing diuretic actions
of trimethoprim: Inhibition of Na channels in A6 distal nephron
cells. Kidney mt 45:1070—1076, 1994
14. ALFERN Ri, STONE DK, RECTOR FC JR: Renal acidification mecha-
nisms, in The Kidney (4th ed), edited by BRENNER BM, RECTOR FC JR,
Philadelphia, W.B. Saunders Co., 1991, p 318
15. SABATINI 5, KURTZMAN NA: Pathophysiology of the renal tubular
acidoses. Semin Nephrol 11:202—211, 1991
16. WINGO CS, MAOSEN DM, SMOLKA A, TI5HER CC: H-K-ATPase
immunoreactivity in cortical and outer medullary collecting duet.
Kidney mt 38:985-990, 1990
17. FROMMER JP, LA5KI ME, WES5ON DE, KURTzMAN NA: Internephron
heterogeneity for carbonic anhydrase-independent bicarbonate reab-
sorption in the rat. J Ctin Invest 73:1034—1045, 1984
18. EIAM-ONG 5, KURTZMAN NA, SABATINI S: Regulation of collecting
tubule ATPases by aldosterone and potassium. J C!in Invest 91:2385—
2392, 1993
19. EIAM-ONG 5, Dnos E, SPOHN M, KUR'I'ZMAN NA, SAaATINI S:
H-K-ATPase in distal renal tubular acidosis: Urinary tract obstruc-
tion, lithium, and amiloride. Am J Physiot 265:F875—F880, 1993
20. DOUCET A, MAR5Y 5: Characterization of K-ATPase activity in distal
nephron: Stimulation by potassium depletion. Am J Physiol 253:F418—
F423, 1987
1378 Eiam-ong et al: Trimethoprim and renal ATPases
21. SABATINI S, LASKI ME, KURTZMAN NA: NEM-sensitive ATPase
activity in rat nephron: Effect of metabolic acidosis and alkalosis. Am
J Physiol 258:F297—F304, 1990
22. DAFNI5 E, KURTZMAN NA, SABATINI S: Effect of lithium and amiloride
on collecting tubule transport enzymes. J Pharmacol Expt Ther 261:
701—706, 1992
23. SCHWARTZ DE, RIEDER J: Pharmacokinetics of sulfamethoxazole and
trimethoprim in man and their distribution in the rat. Chemotherapy
15:337—355, 1970
24. KAPLAN SA, WEtNFELD RE, ABRUZZO CW, MEFADEN K, JACK ML,
WEISSMAN L: Pharmacokinetic profile of trimethoprim-sulfamethox-
azole in man. J Infect Dis 128:S547—S555, 1973
25. CRAIG WA, KuNIN CM: Distribution of trimethoprim-sulfamethox-
azole in tissues of rhesus monkeys. J Infect Dis 128:S575—S579, 1973
26. RIEDER J: Metabolism and techniques for assay of trimethoprim and
sulfamethoxazole. J Infect Dis 128:S567—S573, 1973
27. KALIN MF, PORETSKY L, SERES DS, ZUMOFF B: Hyporeninemic
hypoaldosteronism associated with acquired immune deficiency syn-
drome. Am J Med 82:1035—1038, 1987
28. CH0I MJ, FERNANDEZ PC, PATNAIK A, COUPAYE-GERARD B,
D'ANDREA D, SZERLIP H, KLEYMAN TR: Brief report: Trimethoprim-
induced hyperkalemia in a patient with aids. N Engi J Med 328:703—
706, 1993
29. SOLTOFF SP, CRAGOE EJ, MANDEL U: Amiloride analogues inhibit
proximal tubule metabolism. Am J Physiol 250:C744—C747, 1986
30. GARG LC, NARANG N: Ouabain-insensitive K-adenosine triphos-
phatase in distal nephron segments of the rabbit. J Clin Invest
81:1204—1208, 1988
